Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo

Harati,Kamran; Emmelmann,Sabine; Behr,Björn; Goertz,Ole; Hirsch,Tobias; Kapalschinski,Nicolai; Kolbenschlag,Jonas; Stricker,Ingo; Tannapfel,Andrea; Lehnhardt,Marcus; Daigeler,Adrien

doi:10.3892/ol.2016.4118

Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo

Authors:
- Kamran Harati
- Sabine Emmelmann
- Björn Behr
- Ole Goertz
- Tobias Hirsch
- Nicolai Kapalschinski
- Jonas Kolbenschlag
- Ingo Stricker
- Andrea Tannapfel
- Marcus Lehnhardt
- Adrien Daigeler
View Affiliations

Affiliations: Department of Plastic Surgery, Burn Center, Hand Center, Sarcoma Reference Center, BG‑University Hospital Bergmannsheil, Bochum D‑44789, Germany, Institute of Pathology, Ruhr‑University Bochum, Bochum D‑44789, Germany
Published online on: January 15, 2016 https://doi.org/10.3892/ol.2016.4118
Pages: 1955-1961

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibrosarcomas are rare malignant soft tissue tumours that exhibit a poor response to current therapeutic regimens. Previously, tumour necrosis factor‑related apoptosis‑inducing ligand (TRAIL) and taurolidine were observed to induce apoptosis synergistically in HT1080 human fibrosarcoma cells in vitro. Consequently, the present study aimed to assess the safety and efficacy of TRAIL in combination with taurolidine on the local growth of fibrosarcoma xenografts in vivo. HT1080 fibrosarcoma cells were inoculated subcutaneously into both flanks of 49 athymic nude mice in order to establish tumour xenografts. TRAIL and taurolidine were applied intraperitoneally at various single and cumulative treatment doses. After 12 days, the experiment was terminated and surviving animals were euthanised. Tumour progression was determined during and following treatment. To assess the potential toxic effects of the two compounds, the organs (lung, liver, kidney and heart) of all animals were examined histologically. The results revealed that combined treatment with TRAIL and taurolidine significantly inhibited the growth of HT1080 xenografts, whereas untreated animals had steadily increasing tumours. The most effective combination was TRAIL at 2 µg per application (cumulative dose, 16 µg) and taurolidine at 30/15 mg per application (cumulative dose, 180 mg), reducing the mean size of implanted xenografts to 10.9 mm2 following treatment (vs. 48.9 mm2 in the control group; P=0.0100). Despite distinct tumour mass reduction, the rate of mortality was significantly increased in animals treated with TRAIL and taurolidine in a taurolidine dose‑dependent manner; however, histological examinations of relevant organs revealed no evidence of systemic toxicity (mean survival time, 7.9 days in the treated groups vs. 12 days in the control group; P<0.0010). In summary, whilst the combination of TRAIL and taurolidine synergistically inhibited the growth of fibrosarcoma xenografts in vivo, it was also accompanied by significantly increased mortality rate. Thus, although taurolidine is assumed to be a compound with an acceptable toxicity profile, and therefore increasingly used in clinical trials, the current findings raise concerns with regard to its safety and therapeutic index, and indicate the requirement for further detailed toxicity tests.

View Figures

View References

1	Nedea EA and DeLaney TF: Sarcoma and skin radiation oncology. Hematol Oncol Clin North Am. 20:401–429. 2006. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar : PubMed/NCBI
3	Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P and Rosai J: Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: A series of patients treated at a single institution. J Clin Oncol. 23:96–104. 2005. View Article : Google Scholar : PubMed/NCBI
4	Patrikidou A, Domont J, Cioffi A and Le Cesne A: Treating soft tissue sarcomas with adjuvant chemotherapy. Current Treat Options Oncol. 12:21–31. 2011. View Article : Google Scholar
5	Kaushal A and Citrin D: The role of radiation therapy in the management of sarcomas. Surg Clin North Am. 88:629–646. 2008. View Article : Google Scholar : PubMed/NCBI
6	O'Brien GC, Cahill RA, Bouchier-Hayes DJ and Redmond HP: Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Ir J Med Sci. 175:10–14. 2006. View Article : Google Scholar
7	Solomon LR, Cheesbrough JS, Bhargava R, Mitsides N, Heap M, Green G and Diggle P: Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis. Semin Dial. 25:233–238. 2012. View Article : Google Scholar : PubMed/NCBI
8	Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C and Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 112:1585–1591. 2008. View Article : Google Scholar : PubMed/NCBI
9	Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM and Brennan MF: Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 85:389–395. 1999. View Article : Google Scholar : PubMed/NCBI
10	Pezzi CM, Pollock RE, Evans HL, Lorigan JG, Pezzi TA, Benjamin RS and Romsdahl MM: Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg. 211:476–481. 1990. View Article : Google Scholar : PubMed/NCBI
11	Di Donato Paola E and Nielsen OS: EORTC Soft Tissue and Bone Sarcoma Group: The EORTC soft tissue and bone sarcoma group: The EORTC soft tissue and bone sarcoma group. European organisation for research and treatment of cancer. Eur J Cancer. 38(Suppl 4): S138–S141. 2002.PubMed/NCBI
12	Brodowicz T, Schwameis E, Widder J, Amann G, Wiltschke C, Dominkus M, Windhager R, Ritschl P, Pötter R, Kotz R and Zielinski CC: Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: A prospective randomized feasibility trial. Sarcoma. 4:151–160. 2000. View Article : Google Scholar : PubMed/NCBI
13	Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol. 19:1238–1247. 2001.PubMed/NCBI
14	Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, et al: Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol. 15:415–423. 2014. View Article : Google Scholar : PubMed/NCBI
15	Yagita H, Takeda K, Hayakawa Y, Smyth MJ and Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 95:777–783. 2004. View Article : Google Scholar : PubMed/NCBI
16	Bouralexis S, Findlay DM and Evdokiou A: Death to the bad guys: Targeting cancer via Apo2L/TRAIL. Apoptosis. 10:35–51. 2005. View Article : Google Scholar : PubMed/NCBI
17	Rowinsky EK: Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 23:9394–9407. 2005. View Article : Google Scholar : PubMed/NCBI
18	Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
19	Daniel P: Molecular principles of apoptosis. Principles of Molecular Medicine. Ganten D and Ruckpaul K: (3rd). (Berlin Heidelberg). Springer. 159–203. 2008.
20	Newsom-Davis T, Prieske S and Walczak H: Is TRAIL the holy grail of cancer therapy? Apoptosis. 14:607–623. 2009. View Article : Google Scholar : PubMed/NCBI
21	LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10:66–75. 2003. View Article : Google Scholar : PubMed/NCBI
22	Chromik AM, Daigeler A, Bulut D, Flier A, May C, Harati K, Roschinsky J, Sülberg D, Ritter PR, Mittelkötter U, et al: Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. J Exp Clin Cancer Res. 29:212010. View Article : Google Scholar : PubMed/NCBI
23	Jacobi CA, Menenakos C and Braumann C: Taurolidine-a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs. 16:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
24	McCourt M, Wang JH, Sookhai S and Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol. 7:685–691. 2000. View Article : Google Scholar : PubMed/NCBI
25	Petrovic L, Schlegel KA, Ries J, Park J, Diebel E, Schultze-Mosgau S and Wiltfang J: In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity. Mund Kiefer Gesichtschir. 7:102–107. 2003.(In German). View Article : Google Scholar : PubMed/NCBI
26	Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, Buerk DG, Nedeau A, Thom SR and Velazquez OC: Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest. 117:1249–1259. 2007. View Article : Google Scholar : PubMed/NCBI
27	Calabresi P, Goulette FA and Darnowski JW: Taurolidine: Cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res. 61:6816–6821. 2001.PubMed/NCBI
28	Braumann C, Henke W, Jacobi CA and Dubiel W: The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer. 112:225–230. 2004. View Article : Google Scholar : PubMed/NCBI
29	Darnowski JW, Goulette FA, Cousens LP, Chatterjee D and Calabresi P: Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol. 54:249–258. 2004.PubMed/NCBI
30	Stendel R, Biefer HR, Dékány GM, Kubota H, Münz C, Wang S, Mohler H, Yonekawa Y and Frei K: The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy. 5:194–210. 2009. View Article : Google Scholar : PubMed/NCBI
31	Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M and Möhler H: Enhancement of fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res. 23:2309–2314. 2003.PubMed/NCBI
32	Chromik AM, Daigeler A, Hilgert C, Bulut D, Geisler A, Liu V, Otte JM, Uhl W and Mittelkötter U: Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Invest Surg. 20:339–348. 2007. View Article : Google Scholar : PubMed/NCBI
33	Daigeler A, Chromik AM, Geisler A, Bulut D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W and Mittelkötter U: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol. 32:1205–1220. 2008. View Article : Google Scholar : PubMed/NCBI
34	Daigeler A, Chromik AM, Haendschke K, Emmelmann S, Siepmann M, Hensel K, Schmitz G, Klein-Hitpass L, Steinau HU, Lehnhardt M and Hauser J: Synergistic effects of sonoporation and taurolidin/TRAIL on apoptosis in human fibrosarcoma. Ultrasound Med Biol. 36:1893–1906. 2010. View Article : Google Scholar : PubMed/NCBI
35	Karlisch C, Harati K, Chromik AM, Bulut D, Klein-Hitpass L, Goertz O, Hirsch T, Lehnhardt M, Uhl W and Daigeler A: Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma. Int J Oncol. 42:945–956. 2013.PubMed/NCBI
36	Daigeler A, Brenzel C, Bulut D, Geisler A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinstraesser L, Klein-Hitpass L, et al: TRAIL and taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res. 27:822008. View Article : Google Scholar : PubMed/NCBI
37	Sun BS, Wang JH, Liu LL, Gong SL and Redmond HP: Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. J Surg Oncol. 96:241–248. 2007. View Article : Google Scholar : PubMed/NCBI
38	Nici L, Monfils B and Calabresi P: The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res. 10:7655–7661. 2004. View Article : Google Scholar : PubMed/NCBI
39	Arlt MJ, Walters DK, Banke IJ, Steinmann P, Puskas GJ, Bertz J, Rentsch KM, Ehrensperger F, Born W and Fuchs B: The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity. Int J Cancer. 131:E804–E812. 2012. View Article : Google Scholar : PubMed/NCBI
40	Marley K, Helfand SC, Simpson J, Mata JE, Tracewell WG, Brownlee L, Bracha S and Séguin B: Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma. J Exp Clin Cancer Res. 32:742013. View Article : Google Scholar : PubMed/NCBI
41	Marley K, Helfand SC, Edris WA, Mata JE, Gitelman AI, Medlock J and Séguin B: The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro. BMC Vet Res. 9:152013. View Article : Google Scholar : PubMed/NCBI
42	Braumann C, Winkler G, Rogalla P, Menenakos C and Jacobi CA: Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol. 4:342006. View Article : Google Scholar : PubMed/NCBI
43	Möhler H, Pfirrmann RW and Frei K: Redox-directed cancer therapeutics: Taurolidine and piperlongumine as broadly effective antineoplastic agents (review). Int J Oncol. 45:1329–1336. 2014.PubMed/NCBI
44	Imhof L, Goldinger SM, Baumann K, Schad K, French LE, Röthlisberger P and Dummer R: The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: Results of a phase 2, open-label study. Melanoma Res. 21:80–83. 2011. View Article : Google Scholar : PubMed/NCBI
45	Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Jänisch W and Brock M: Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res. 24:1143–1147. 2004.PubMed/NCBI